News & Updates
Filter by Specialty:
SC infliximab dose escalation restores efficacy, elicits rapid response in IBD
A retrospective analysis has shown that increasing the dose of subcutaneous infliximab (CT-P13 SC) from 120 to 240 mg Q2W in patients with inflammatory bowel disease who initially responded but subsequently lost response leads to improved clinical efficacy over an extended period.
SC infliximab dose escalation restores efficacy, elicits rapid response in IBD
24 Feb 2025
Can sintilimab maintain or improve HRQoL in 1L treatment of NSCLC?
Addition of sintilimab to pemetrexed and platinum-based chemotherapy maintained or improved health-related quality of life (HRQoL) and symptoms compared with chemotherapy alone in first-line (1L) treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), according to a prespecified exploratory analysis of the phase III ORIENT-11 trial.
Can sintilimab maintain or improve HRQoL in 1L treatment of NSCLC?
24 Feb 2025
Long-term colchicine use helps prevent stroke, cardiac events
Treatment with colchicine appears to lower the risk of stroke and major adverse cardiovascular events (MACE) when used for longer duration, according to a study presented at ISC 2025. This beneficial effect, however, is not observed among patients with shorter follow-up duration.
Long-term colchicine use helps prevent stroke, cardiac events
23 Feb 2025
EVT-IVT combo better than EVT alone in patients with large core infarct
The addition of intravenous thrombolysis (IVT) to endovascular thrombectomy (EVT) provides significant clinical benefits to patients who experienced acute ischaemic stroke (AIS) caused by large vessel occlusion (LVO) with large ischaemic infarcts (LII), as shown by the findings of a meta-analysis presented at the recent ISC 2025.
